Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:31:55 2024-05-08 am EDT			5-day change	1st Jan Change
90.54 ^CHF	+0.85%		+1.88%	+6.68%

May. 06	NOVARTIS AG : UBS maintains a Buy rating	ZD
May. 02	Health Care Flat Amid Mixed Earnings -- Health Care Roundup	DJ

NOVARTIS AG : Goldman Sachs reaffirms its Buy rating

July 07, 2021 at 03:41 am EDT

Already positive, the research from Goldman Sachs and its analyst Keyur Parekh still consider the stock as a Buy opportunity. The target price has been lifted and is now set at CHF 110 compared to CHF 106 before.

Latest news about Novartis AG

NOVARTIS AG : UBS maintains a Buy rating	May. 06	ZD
Health Care Flat Amid Mixed Earnings -- Health Care Roundup	May. 02	DJ
Sector Update: Health Care Stocks Softer Late Afternoon	May. 02	MT
Sector Update: Health Care Stocks Retreat Thursday Afternoon	May. 02	MT
Top Midday Stories: Novo Nordisk, Linde Shares Fall Post-Earnings; Peloton Shares Plummet After Announcing Job Cuts, CEO Change; Exxon-Pioneer Deal Gets FTC Approval With One Caveat	May. 02	MT
News Highlights : Top Company News of the Day - Thursday at 11 AM ET	May. 02	DJ
Novartis AG to Acquire Mariana Oncology in Deal Valued Up to $1.75 Billion.	May. 02	MT
News Highlights : Top Company News of the Day - Thursday at 9 AM ET	May. 02	DJ
Novartis: acquisition of US-based Mariana Oncology	May. 02	CF
Switzerland's Novartis to Buy US-based Mariana Oncology for $1 Billion Upfront	May. 02	MT
Novartis to Buy Mariana Oncology, Pay $1 Billion Upfront	May. 02	MT
Novartis AG to Acquire Mariana Oncology	May. 02	MT
Novartis AG to Acquire Mariana Oncology	May. 02	MT
Novartis to Buy Mariana Oncology for Up to $1.75 Billion in Boost to Radioligand Therapy Business	May. 02	DJ
Novartis to buy radiology specialist Mariana Oncology for $1 billion	May. 02	RE
Chimeric Therapeutics Appoints COO; Shares Rise 4%	May. 01	MT
Novartis AG entered into an agreement to acquire Mariana Oncology, Inc. from Atlas Venture L.P., Access Biotechnology, RA Capital Management, L.P., Deep Track Capital, LP, Forbion Capital Partners B.V. and others for $1.8 billion.	May. 01	CI
Avacta picks Christina Coughlin to replace long-serving CEO	May. 01	AN
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	Apr. 30	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	Apr. 30	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	Apr. 30	MT
Peptidream Announces Expansion of Peptide Discovery Collaboration with Novartis	Apr. 30	CI
Novartis target Morphosys multiplies losses - takeover schedule stands	Apr. 29	DP
Morphosys says takeover by Novartis on course after report of drug safety concern	Apr. 29	RE
NOVARTIS AG : Receives a Buy rating from Jefferies	Apr. 26	ZD

Chart Novartis AG

Duration

Period

More charts

Company Profile

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).

Sector

Pharmaceuticals

Calendar

2024-05-22 - Deutsche Bank dbAccess European Champions Conference

Related indices

SMI , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

NOVARTIS : 2024 has started on a strong note; guidance upgraded

April 23, 2024 at 01:24 pm EDT

Vas Narasimhan, CEO of Novartis: 40% margin by 2027

April 23, 2024 at 07:18 am EDT

Novartis AG : Sandoz takes its first steps on the stock exchange

October 04, 2023 at 10:32 am EDT

More Strategies

Ratings for Novartis AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

99 USD

Average target price

108.4 USD

Spread / Average Target

+9.54%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVARTIS AG	+6.68%	202B
ELI LILLY AND COMPANY	+33.09%	700B
JOHNSON & JOHNSON	-4.92%	358B
MERCK & CO., INC.	+18.84%	330B
ABBVIE INC.	+3.52%	287B
ASTRAZENECA PLC	+15.70%	236B
ROCHE HOLDING AG	-9.08%	197B
AMGEN INC.	+5.99%	161B
PFIZER, INC.	-1.95%	157B
SANOFI	+3.70%	124B

Other Pharmaceuticals

Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

NOVARTIS AG : Goldman Sachs reaffirms its Buy rating

EPS Revisions